Repository logo
 
Publication

Initial Results of the International Efforts in Screening New Agents against Candida auris

2022-07-25Journal article Open access
Simple item page
dc.contributor.authorPoester, Vanice Rodrigues
dc.contributor.authorMunhoz, Lívia Silveira
dc.contributor.authorBenelli, Jéssica Louise
dc.contributor.authorMelo, Aryse Martins
dc.contributor.authorAl-Hatmi, Abdullah M.S.
dc.contributor.authorLarwood, David J.
dc.contributor.authorMartinez, Marife
dc.contributor.authorStevens, David A.
dc.contributor.authorXavier, Melissa Orzechowski
dc.date.accessioned2023-03-16T12:24:00Z
dc.date.available2023-03-16T12:24:00Z
dc.date.issued2022-07-25
dc.descriptionThis article belongs to the Special Issue Biology, Immunology, Epidemiology, and Therapy of Fungal Infections: A Themed Issue Dedicated to Professor David A. Stevens.
dc.description.abstractBackground: Candida auris is an emergent fungal pathogen and a global concern, mostly due to its resistance to many currently available antifungal drugs. Objective: Thus, in response to this challenge, we evaluated the in vitro activity of potential new drugs, diphenyl diselenide (PhSe)2 and nikkomycin Z (nikZ), alone and in association with currently available antifungals (azoles, echinocandins, and polyenes) against Candida auris. Methods: Clinical isolates of C. auris were tested in vitro. (PhSe)2 and nikZ activities were tested alone and in combination with amphotericin B, fluconazole, or the echinocandins, micafungin and caspofungin. Results: (PhSe)2 alone was unable to inhibit C. auris, and antagonism or indifferent effects were observed in the combination of this compound with the antifungals tested. NikZ appeared not active alone either, but frequently acted cooperatively with conventional antifungals. Conclusion: Our data show that (PhSe)2 appears to not have a good potential to be a candidate in the development of new drugs to treat C. auris, but that nikZ is worthy of further study.pt_PT
dc.description.sponsorshiphis work was accomplished with support from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil, within the scope of the Capes-PrInt Program—Financing Code 001pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Fungi (Basel). 2022 Jul 25;8(8):771. doi: 10.3390/jof8080771pt_PT
dc.identifier.doi10.3390/jof8080771pt_PT
dc.identifier.issn2309-608X
dc.identifier.urihttp://hdl.handle.net/10400.18/8551
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relation.publisherversionhttps://www.mdpi.com/2309-608X/8/8/771pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCandida aurispt_PT
dc.subjectCandida Speciespt_PT
dc.subjectAntifungal Drugspt_PT
dc.subjectChitin Synthase Inhibitorpt_PT
dc.subjectDiphenyl Diselenidept_PT
dc.subjectin vitro Susceptibility Assayspt_PT
dc.subjectNikkomycin Zpt_PT
dc.subjectOrganoselenium Compoundspt_PT
dc.subjectInfecções Sistémicas e Zoonosespt_PT
dc.titleInitial Results of the International Efforts in Screening New Agents against Candida aurispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue8pt_PT
oaire.citation.startPage771pt_PT
oaire.citation.titleJournal of Fungipt_PT
oaire.citation.volume8pt_PT
rcaap.embargofctAcesso de acordo com política editorial da revista.pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jof-08-00771.pdf
Size:
283.11 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DDI - Artigos em revistas internacionais